Kinases are arguably one of the most important drug targets due to the roles their mutations, overexpression, and dysregulation play in all major pathologies, including immunological, inflammatory, degenerative, metabolic, cardiovascular, and infectious diseases. This is because kinases drive nearly every signal transduction process in the body.
Kinases catalyze the transfer of phosphate groups. Based upon the nature of the phosphorylated groups, these enzymes are classified as serine/threonine kinases, tyrosine kinases (including both receptor and non-receptor proteins), and tyrosine kinase-like enzymes. A small group of enzymes including MEK1/2, which catalyze the phosphorylation of both threonine and tyrosine residues within the activation segment of target proteins, are classified as dual specificity kinases.
More than 200 different orally effective protein kinase inhibitors are in clinical trials worldwide. A regularly updated listing of these trials can be found here. Notably, these compounds are directed against a small fraction (~40 different protein kinases) of the more than 500 members of the human protein kinase super family. The most common drug targets include ALK, B-RAF, Bcr-Abl, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor (VEGFR). Available antibodies, inhibitors, and screening libraries are enabling the drug discovery field to validate novel kinase targets, overcome drug resistance, obtain target selectivity (to reduce off-target effects), and develop efficient compound screening and profiling technologies.
Explore 1,155+ Kinase Inhibitors From Cayman Chemical
Click on any of the circles in the pathway image below to find inhibitors targeting specific kinases
Signal transduction pathways for major kinases. Turquoise circles represent protein kinases, octagons represent related proteins, and pentagons represent second-messengers. Adapted from the Harvard Medical School LINCS Center. Download this kinase pathway chart from Cayman.
Select Kinase Antibodies From Rockland Immunochemicals
Rockland Immunochemicals has a long-established history of providing critical antibodies for kinase research:
Simplify Screening and Hit-Seeking
- Consists of 11 plates with more than 850 selective and non-selective kinase inhibitors
- Includes inhibitors of lipid, receptor and non-receptor tyrosine, serine/threonine, and dual specificity kinases
- Targets include ROCK, ALK, GSK3, PKC, PDGFR, VEGFR, Src, MAPK, CDK, and PI3K families, among many others